Home Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
 

Keywords :   


Ligand Earns Milestone from SAGE Therapeutics for SAGE-547

2015-04-22 21:34:03| Biotech - Topix.net

Ligand Pharmaceuticals Incorporated today announced that it has earned a $500,000 milestone payment from SAGE Therapeutics relating to the treatment of the first patient in SAGE's Phase 3 open-label expanded access protocol, designated Study 302. Study 302 is designed to offer SAGE-547 to patients affected by super-refractory status epilepticus and to evaluate the safety of SAGE-547 in patients with SRSE.

Tags: sage milestone earns therapeutics

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
More »